Previous Close | 63.42 |
1-Year Change | -27.28% |
6-Months Change | -18.23% |
3-Months Change | -31.63% |
Moving Avg (50d) | 70.434 |
Moving Avg (200d) | 81.604 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 11.9B |
Beta (3-Years) | 0.71 |
Revenue Growth (ttm) | 15.05% |
Net Profit Margin (ttm) | 6.36% |
Return On Assets (ttm) | 2.18% |
EPS (ttm) | 0.77 |
PE Ratio (ttm) | 82.36 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also... Wikipedia